A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2017
At a glance
- Drugs PF 06835919 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- Sponsors Pfizer
- 16 Feb 2017 Status changed from suspended to completed.
- 06 Jan 2017 Status changed from active, no longer recruiting to suspended.
- 21 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.